UroGen Historical Income Statement
| URGN Stock | USD 11.40 0.50 4.20% |
Historical analysis of UroGen Pharma income statement accounts such as Depreciation And Amortization of 994.3 K, Interest Expense of 13.1 M, Selling General Administrative of 127.2 M or Total Revenue of 94.9 M can show how well UroGen Pharma performed in making a profits. Evaluating UroGen Pharma income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of UroGen Pharma's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining UroGen Pharma latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether UroGen Pharma is a good buy for the upcoming year.
UroGen |
About UroGen Income Statement Analysis
UroGen Pharma Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to UroGen Pharma shareholders. The income statement also shows UroGen investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
UroGen Pharma Income Statement Chart
Add Fundamental
Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of UroGen Pharma. It is also known as UroGen Pharma overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Total Operating Expenses
The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.Most accounts from UroGen Pharma's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into UroGen Pharma current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in UroGen Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. To learn how to invest in UroGen Stock, please use our How to Invest in UroGen Pharma guide.At this time, UroGen Pharma's Income Tax Expense is very stable compared to the past year. As of the 26th of March 2025, Interest Income is likely to grow to about 9.3 M, while Depreciation And Amortization is likely to drop about 994.3 K.
UroGen Pharma income statement Correlations
Click cells to compare fundamentals
UroGen Pharma Account Relationship Matchups
High Positive Relationship
High Negative Relationship
UroGen Pharma income statement Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Depreciation And Amortization | 2.0M | 1.8M | 1.8M | 1.7M | 1.2M | 994.3K | |
| Interest Expense | 3.7M | 17.4M | 8.4M | 14.7M | 12.5M | 13.1M | |
| Selling General Administrative | 90.2M | 39.9M | 82.8M | 90.4M | 121.2M | 127.2M | |
| Total Revenue | 11.8M | 48.0M | 64.4M | 82.7M | 90.4M | 94.9M | |
| Gross Profit | 10.8M | 42.9M | 56.7M | 73.4M | 81.5M | 85.6M | |
| Other Operating Expenses | 138.5M | 140.3M | 143.4M | 148.2M | 187.2M | 196.5M | |
| Operating Income | (126.7M) | (92.3M) | (79.0M) | (65.5M) | (96.8M) | (91.9M) | |
| Net Income From Continuing Ops | (128.5M) | (110.8M) | (109.8M) | (105.1M) | (126.9M) | (120.5M) | |
| Ebit | (126.7M) | (91.9M) | (79.8M) | (65.5M) | (111.5M) | (105.9M) | |
| Research Development | 47.3M | 47.6M | 52.9M | 45.6M | 57.1M | 35.1M | |
| Ebitda | (124.7M) | (90.2M) | (78.0M) | (63.8M) | (110.3M) | (104.8M) | |
| Cost Of Revenue | 1.0M | 5.2M | 7.7M | 9.4M | 8.9M | 9.3M | |
| Total Operating Expenses | 137.5M | 135.2M | 135.7M | 138.9M | 178.3M | 89.5M | |
| Income Before Tax | (125.1M) | (109.4M) | (108.0M) | (98.3M) | (124.0M) | (117.8M) | |
| Total Other Income Expense Net | 1.6M | (17.1M) | (29.0M) | (32.8M) | (27.3M) | (25.9M) | |
| Net Income Applicable To Common Shares | (105.1M) | (128.5M) | (110.8M) | (109.8M) | (98.8M) | (93.9M) | |
| Net Income | (128.5M) | (110.8M) | (109.2M) | (102.2M) | (126.9M) | (120.5M) | |
| Income Tax Expense | 3.4M | 1.4M | 1.1M | 3.9M | 2.8M | 3.0M | |
| Interest Income | 2.0M | 365K | 938K | 2.4M | 8.9M | 9.3M | |
| Net Interest Income | 1.6M | 212K | (7.4M) | (11.9M) | (3.6M) | (3.4M) | |
| Tax Provision | 3.4M | 1.4M | 1.8M | 755K | 2.8M | 1.4M | |
| Reconciled Depreciation | 2.0M | 1.8M | 1.8M | 1.7M | 1.2M | 1.4M |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in UroGen Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. To learn how to invest in UroGen Stock, please use our How to Invest in UroGen Pharma guide.You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of UroGen Pharma. If investors know UroGen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about UroGen Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.96) | Revenue Per Share | Quarterly Revenue Growth 0.044 | Return On Assets | Return On Equity |
The market value of UroGen Pharma is measured differently than its book value, which is the value of UroGen that is recorded on the company's balance sheet. Investors also form their own opinion of UroGen Pharma's value that differs from its market value or its book value, called intrinsic value, which is UroGen Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because UroGen Pharma's market value can be influenced by many factors that don't directly affect UroGen Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between UroGen Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if UroGen Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, UroGen Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.